Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jul;13(3):339-354.
doi: 10.1016/j.cpet.2018.02.006.

Overview of Breast Cancer Therapy

Tracy-Ann Moo  1 , Rachel Sanford  2 , Chau Dang  2 , Monica Morrow  3
Affiliations
Review

Overview of Breast Cancer Therapy

Tracy-Ann Moo et al. PET Clin. 2018 Jul.

Abstract

Breast cancer treatment is multidisciplinary. Most women with early stage breast cancer are candidates for breast-conserving surgery with radiotherapy or mastectomy. The risk of local recurrence and the chance of survival does not differ with these approaches. Sentinel node biopsy is used for axillary staging, and individualized approaches are minimizing the need for axillary dissection in women with positive sentinel nodes. Adjuvant systemic therapy is used in most women based on proven survival benefit, and molecular profiling to individualize treatment based on risk is now a clinical reality for patients with hormone receptor-positive cancers.

Keywords: Adjuvant therapy; Breast cancer surveillance; Breast cancer therapy; Breast-conserving therapy; Endocrine therapy; Local therapy; Mastectomy; Neoadjuvant chemotherapy.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Invasive breast cancer: Algorithm for local therapy
SLNB, sentinel lymph node biopsy; BCT, breast-conserving therapy; ALND, axillary lymph node dissection; XRT, breast radiation; SLN, sentinel lymph node; PMRT, postmastectomy radiation therapy
Figure 2
Figure 2. TAILORx for node-negative, hormone receptor-positive and HER2-negative breast cancer
RS: recurrence score
Figure 3
Figure 3. RxPONDER for node-positive, hormone receptor-positive and HER2-negative breast cancer
RS: recurrence score
See this image and copyright information in PMC

References

    1. Hortobagyi GN, Buzdar AU. Management of locally advanced breast cancer. Am J Clin Oncol. 1988;11(5):597–601. - PubMed
    1. Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347(16):1233–41. - PubMed
    1. Veronesi U, Cascinelli N, Mariani L, Greco M, Saccozzi R, Luini A, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med. 2002;347(16):1227–32. - PubMed
    1. Poggi MM, Danforth DN, Sciuto LC, Smith SL, Steinberg SM, Liewehr DJ, et al. Eighteen-year results in the treatment of early breast carcinoma with mastectomy versus breast conservation therapy: the National Cancer Institute Randomized Trial. Cancer. 2003;98(4):697–702. - PubMed
    1. Voogd AC, Nielsen M, Peterse JL, Blichert-Toft M, Bartelink H, Overgaard M, et al. Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials. J Clin Oncol. 2001;19(6):1688–97. - PubMed